Zymergen, an Emeryville, Calif.-based science and material innovation company, raised $300M in funding.
The investment included initial Series D funding led by Baillie Gifford, joined by Baron Capital Group and one of the world’s largest sovereign wealth funds, as well as additional growth financing from Perceptive Advisors. A number of current investors are also returning, and Zymergen expects to raise additional capital in Q4 as part of a Series D round.
This capital allows the company to speed the manufacture of their Hyaline film, as well as to commercialize additional breakthrough products across electronics, agriculture, consumer care and healthcare.
Led by CEO Josh Hoffman, Zymergen leverages a proprietary platform combining biology, chemistry, machine learning and lab automation to discover, design and commercialize products across industries – from agriculture to electronics, consumer care to pharmaceuticals, and more
It is launching Hyaline, a new film for electronics application, and is advancing all-natural pesticides, other bio-derived crop protection products, as well as a bio-based insect repellent.